DataMeds AI Signs Nonbinding Deal to License and Acquire Healthcare IP
Bitget2026/10/22 11:45- DataMeds AI entered an amended, nonbinding agreement dated October 19, 2026, to acquire and license healthcare intellectual property.
- Proposed acquisitions cover EOS Technology Holdings’ medication delivery patents and Scilex’s wearable-based drug-response verification patents.
- Licensing plans include expanded healthcare rights from Datavault AI and exclusive patient-outcomes technology from Data Health Partners.
- Closing is targeted for the fourth quarter of 2026, subject to definitive agreements, due diligence and Nasdaq requirements.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Report: Apple Plans to Establish Multi-Year DRAM Agreement with Samsung, Deliveries to Begin in First Half of 2027
Apple and Samsung are in negotiations for a long-term DRAM chip supply agreement lasting four to five years, with deliveries expected to start in the first half of 2027. The agreement is expected to include a minimum supply commitment and set pricing linked to the market. Currently, Apple is one of the few major tech companies that have yet to sign a long-term DRAM supply deal with Samsung.

Bitcoin's $90,000 Comeback Now Unlikely, Novogratz Warns

MMT rises over 50% again, currently trading at $0.2144

Anthropic’s IPO Pricing Is Today: Here’s What Investors Should Expect